In addition, the presence of B lymphocytes (CD20+) has been associated with higher pCR rates after anthracycline–taxane-based neoadjuvant treatment [55,72], as well as after dual HER2 blockade (without chemotherapy) in HER2+ BC patients [65]. The gene discussed is ERBB2; the disease is breast cancer.